In nasopharyngeal carcinoma, METTL1 increases the conversion of EMT through the WNT/β- catenin signaling pathway, leading to chemoresistance to cisplatin and docetaxel in vitro and in vivo [76]. This evidence concerns the gene METTL1 and nasopharyngeal carcinoma.